| Quarter | Score |
|---|---|
| 2022-Q3 | 65.5 |
| 2022-Q4 | 49.5 |
| 2023-Q1 | 49.6 |
| 2023-Q2 | 36.2 |
| 2023-Q3 | 48.1 |
| 2023-Q4 | 52.4 |
| 2024-Q1 | 70.3 |
| 2024-Q2 | 67.8 |
| 2024-Q3 | 76.9 |
| 2024-Q4 | 78.3 |
| 2025-Q1 | 64.5 |
| 2025-Q2 | 81.0 |
| 2025-Q3 | 82.0 |
| 2025-Q4 | 81.0 |
| 2026-Q1 | 80.2 |
| 2026-Q2 | 78.5 |
Strong consensus, but price is extended — wait for pullback to funds' basis
Trading +83.8% above funds' purchase price — elevated pullback risk
2 of 18 tracked funds hold DHT. Avg conviction: 1.1%. Net holding. First tracked at $10.92 (current +83.8% vs tracked).
Greenlight Capital has 2.1% in this stock
Prices are approximate, based on 13F reported values (position value / shares), not actual cost basis. Data covers 17 tracked value-oriented funds. Holdings are reported quarterly with a ~45-day lag. Stock splits may affect share count comparisons. Returns are not annualized.
| Fund | % of Portfolio | Action |
|---|---|---|
| Greenlight Capital | 2.1% | Reduce |
| Citadel Advisors | 0.0% | Add |